Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Makihara K, Azuma S, Kawato N, Ueno H, Nakata I. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage. Cancer Chemother Pharmacol 2015;75:273-9. [PMID: 25432775 DOI: 10.1007/s00280-014-2633-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Accepted: 11/14/2014] [Indexed: 12/11/2022]

For:	Makihara K, Azuma S, Kawato N, Ueno H, Nakata I. Pre-treatment serum total bilirubin level as an indicator of optimal CPT-11 dosage. Cancer Chemother Pharmacol 2015;75:273-9. [PMID: 25432775 DOI: 10.1007/s00280-014-2633-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Accepted: 11/14/2014] [Indexed: 12/11/2022]

Number	Cited by Other Article(s)
1	Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy. Med Oncol 2019;36:63. [DOI: 10.1007/s12032-019-1288-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Accepted: 05/28/2019] [Indexed: 01/28/2023] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A. High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy. Med Oncol 2019;36:63. [DOI: 10.1007/s12032-019-1288-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Accepted: 05/28/2019] [Indexed: 01/28/2023]